Search JIM Advanced Search

Journal of Chinese Integrative Medicine ›› 2008, Vol. 6 ›› Issue (2): 153-156.doi: 10.3736/jcim20080209

• Original Clinical Research • Previous Articles     Next Articles

Clinical observation of Yisui Shengxue Granule in treating 25 patients with hemoglobin H disease

Wen-juan Wang1, Zhi-kui Wu1(), Xin-hua Zhang2, Yong-mei Liu1, Su-ping Fang1, Rong-xin Wang2, Chong Zhang1, Tian-hong Zhou2, Ping-ping Li2, Rui-gui Luo2   

  1. 1. Department of Molecular Biology, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing 100053, China
    2. Department of Haematology, 303 Hospital of Peoples Liberation Army of China, Nanning, Guangxi Zhuang Autonomous Region 530021, China
  • Received:2007-04-09 Online:2008-02-20 Published:2008-02-15
  • Contact: WU Zhi-kui E-mail:gamwuzhikui@sina.com

Objective:To investigate the clinical efficacy and safety of Yisui Shengxue Granule (YSSXG), a compound traditional Chinese herbal medicine for reinforcing kidney and nourishing blood, in treating hemoglobin H (HbH) disease.

Methods:YSSXG was given orally to 25 patients with HbH disease in Guangxi Zhuang Autonomous Region (high incidence area for HbH disease in China) for 3 months as one therapeutic course, 3 times a day, 10 g YSSXG was given each time (dose of YSSXG for children should be reduced properly), and blood transfusion was not given to HbH patients during the course of treatment. The levels of hemoglobin (Hb), red blood cell (RBC), HbH and reticulocyte (Ret) were observed before and after YSSXG treatment, and side effects were observed during the course of treatment. Meanwhile, the genotype was examined, and the clinical efficacy of YSSXG in treating HbH patients with different genotype was evaluated.

Results:The levels of Hb, RBC and Ret were obviously increased after YSSXG treatment from the first month to the end of treatment (P<0.01). After YSSXG treatment, the levels of Hb, RBC, Ret in 12 HbH patients with gene deletion were elevated (P<0.05, P<0.01), and the levels of Hb and Ret in 13 HbH patients with gene non-deletion were increased obviously (P<0.05, P<0.01). The total response rate was 84% after 3-month treatment, and there was no statistical difference in clinical efficacy between gene deletion HbH patients and non-deletion HbH patients. No adverse effect was observed during the course of treatment.

Conclusion:YSSXG is effective and safe for treatment of HbH disease. YSSXG can improve the levels of Hb, RBC and Ret in HbH patients, especially in gene deletion HbH patients.

Key words: reinforcing kidney and supplying emission, reinforcing qi and nourishing blood, alpha-thalassemia, clinical trials

CLC Number: 

  • R556

Table 1

Changes of blood indexes in HbH patients before and after YSSXG treatment ($\bar{x}$±s)"

Course of treatment n Hb (g/L) RBC (×1012/L) Ret (%) HbH (%)
Before treatment 25 85.32±12.89 4.61±0.75 7.50±3.76 16.85±4.63
After one-month treatment 25 92.36±12.30** 4.80±0.67** 9.54±3.88** 16.99±4.74
After two-month treatment 24 90.50±11.50** 4.79±0.78** 10.33±3.42** 17.09±4.99
After three-month treatment 25 93.64±12.52** 4.87±0.79** 10.32±4.31** 16.26±4.23

Table 2

Changes of blood indexes in HbH patients with gene deletion before and after YSSXG treatment ($\bar{x}$±s)"

Course of treatment n Hb (g/L) RBC (×1012/L) Ret (%) HbH (%)
Before treatment 12 90.33±11.76 5.08±0.57 4.71±1.85 14.69±5.41
After one-month treatment 12 96.92±10.86* 5.31±0.38* 6.36±1.78** 14.90±5.78
After two-month treatment 11 96.73±7.35** 5.35±0.45** 7.53±1.92** 14.94±5.99
After three-month treatment 12 100.08±8.70** 5.43±0.42* 7.13±2.36** 14.03±4.34

Table 3

Changes of blood indexes in HbH patients with gene non-deletion before and after YSSXG treatment ($\bar{x}$±s)"

Course of treatment n Hb (g/L) RBC (×1012/L) Ret (%) HbH (%)
Before treatment 13 80.69±12.53 4.17±0.64 10.08±3.19 18.85±2.64
After one-month treatment 13 88.15±12.44** 4.33±0.51 12.48±2.78** 18.93±2.41
After two-month treatment 13 85.23±11.95 4.31±0.67 12.69±2.48** 18.91±3.17
After three-month treatment 13 87.69±12.82* 4.35±0.70 13.27±3.54** 18.32±2.99
[1] Zhang ZN. Diagnosis and curative effect evaluation standard of hematopathy. Beijing: Science Press. 1998: 48-59. Chinese.
张之南 . 血液病诊断及疗效标准.北京: 科学出版社. 1998: 48-59.
[2] State Bureau of Technical Supervision. Clinical terminology of traditional Chinese medical diagnosis and treatment of syndromes. Beijing: Standards Press of China. 1997: 2-3, 33-35, 37-40. Chinese.
国家技术监督局. 中华人民共和国国家标准中医临床诊疗术语证候部分.北京: 中国标准出版社.1997: 2-3, 33-35, 37-40.
[3] Zheng XY. Guiding principle of clinical research on Chinese new drugs. Beijing: Chinese Medical Science and Technology Press. 2002: 173- 184, 263-266. Chinese.
郑筱萸 . 中药新药临床研究指导原则.北京: 中国医药科技出版社. 2002: 173- 184, 263-266.
[4] Zhang JW, Long GF. Hemoglobin and hemoglobin disease. Nanning: Guangxi Science and Technology Press. 2003: 204-213. Chinese.
张俊武, 龙桂芳 . 血红蛋白与血红蛋白病.南宁: 广西科学技术出版社. 2003: 204-213.
[5] Zhou YQ, Xiao QZ, Huang LJ , et al. Clinical phenotype genotype correlation in children with hemoglobin H Disease in Zhuhai area of China. Zhonghua Er Ke Za Zhi. 2004; 42(9):693-696. Chinese with abstract in English.
周玉球, 肖奇志, 黄丽娟 , 等. HbH病患儿临床表现与基因型相关性的研究.中华儿科杂志. 2004; 42(9):693-696.
[6] Wu ZK, Zhang XH, Li M , et al. Clinical observation on effects of Yisui Shengxue Granule in treating 156 patients with p-thalassemia. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2006; 26(4):352-354. Chinese with abstract in English.
doi: 10.7661/CJIM.2006.4.352
吴志奎, 张新华, 李敏 , 等. 益髓生血颗粒治疗卩-地中海贫血156例临床观察.中国中西医结合杂志. 2006; 26(4):352-354.
doi: 10.7661/CJIM.2006.4.352
[7] Wu ZK, Zhang XH, Cai HG , et al. Molecular mechanism of Yisui Shengxue Granule in treating patients with β-thalassemia and regulating the expression of globin mRNA. Yi Xue Yan Jiu Za Zhi. 2006; 35(9):36-37. Chinese.
doi: 10.3969/j.issn.1673-548X.2006.09.013
吴志奎, 张新华, 蔡辉国 , 等. 益髓生血颗粒治疗地贫与调控珠蛋白mRNA表达分子机制研究.医学研究杂志. 2006; 35(9):36-37.
doi: 10.3969/j.issn.1673-548X.2006.09.013
[1] Arthur Yin Fan, Hui Ouyang, Xinru Qian, Hui Wei, David Dehui Wang, Deguang He, Haihe Tian, Changzhen Gong, Amy Matecki, Sarah Faggert Alemi. Discussions on real-world acupuncture treatments for chronic low-back pain in older adults. Journal of Integrative Medicine, 2019, 17(2): 71-76.
[2] Shahnaz Karkon Varnosfaderani, Fataneh Hashem-Dabaghian, Gholamreza Amin, Mahbubeh Bozorgi, Ghazaleh Heydarirad, Esmaeil Nazem, Mohsen Nasiri Toosi, Seyed Hamdollah Mosavat. Efficacy and safety of Amla (Phyllanthus emblica L.) in non-erosive reflux disease: A double-blind, randomized, placebo-controlled clinical trial. Journal of Integrative Medicine, 2018, 16(2): 126-131.
[3] Subhranil Saha​, Munmun Koley​, Subhasish Ganguly​, Prasanta Rath​, Pulak Roy Chowdhury, Seikh Intaj Hossain. Developing the criteria for evaluating quality of individualization in homeopathic clinical trialreporting: A preliminary study. Journal of Integrative Medicine, 2014, 12(1): 13-19.
[4] Christoph A. Doenitz, Ana Anjos, Thomas Efferth , Tobias Greten, Henry J. Greten. Can heat and cold be parameterized? Clinical data of a preliminary study. Journal of Chinese Integrative Medicine, 2012, 10(5): 532-537.
[5] Dong-tao Li, Jian Wang , Hong-yang Jiang , Feng-lei Shi , Fu-yu Li , Ji-hong Liu , Yong-mei Cheng , Nan Yan , Ai-hua Hu, Mei-zeng Zhang , Jie Li, Ling-bo Wei , Rong-qin Jiang. Quantitative evaluation of the degrees of traditional Chinese medicine qualitative syndromes of osteoporosis. Journal of Chinese Integrative Medicine, 2012, 10(11): 1254-1262.
[6] Ping Wang , Xu-dong Tang , Bao-yan Liu , Ming-jie Zi . Development of a patient-reported outcome instrument for chronic gastrointestinal diseases: Item selection. Journal of Chinese Integrative Medicine, 2012, 10(10): 1092-1098.
[7] Yu Huang, Xing Zeng, Wei Zhu, Sha-sha Li, Dan Zhou, Chuan-jian Lu. Correlation between T lymphocyte subsets and different syndrome types in patients with influenza A (H1N1): A retrospective study. Journal of Chinese Integrative Medicine, 2011, 9(2): 143-147.
[8] MacPherson H. Towards better reporting of interventions in clinical trials of acupuncture. Journal of Chinese Integrative Medicine, 2010, 8(9): 801-803.
[9] Hugh MacPherson , Douglas G Altman , Richard Hammerschlag , Youping Li , Taixiang Wu , Adrian White, David Moher . Revised STandards for Reporting Interventions in Clinical Trials of Acupuncture (STRICTA): Extending the CONSORT statement (Chinese version). Journal of Chinese Integrative Medicine, 2010, 8(9): 804-818.
[10] David Moher, Sally Hopewell, Kenneth F Schulz, Victor Montori, Peter C Gtzsche, P J Devereaux, Diana Elbourne, Matthias Egger, Douglas G Altman. CONSORT 2010 Explanation and Elaboration: Updated guidelines for reporting parallel group randomised trials (Chinese version). Journal of Chinese Integrative Medicine, 2010, 8(8): 701-741.
[11] Kenneth F Schulz, Douglas G Altman, David Moher, the CONSORT Group. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials (Chinese version). Journal of Chinese Integrative Medicine, 2010, 8(7): 604-612.
[12] J Wu. Placebo control and clinical trial of Chinese medicine. Journal of Chinese Integrative Medicine, 2010, 8(10): 906-910.
[13] Xian-kui Qin, Mei Han, Jian-ping Liu. Compound Chinese herbal medicines, Chinese herbal drugs and their active extracts for treatment of chronic hepatitis C: A systematic review and meta-analysis of randomized clinical trials. Journal of Chinese Integrative Medicine, 2009, 7(10): 913-928.
[14] Xiao-yu Li, Xiao-yun Wang, Guang-ning Nie. Application of complementary and alternative therapies abroad in treatment of climacteric symptoms. Journal of Chinese Integrative Medicine, 2009, 7(1): 89-94.
[15] Yu-tong Fei, Jian-ping Liu. Improving the quality of reporting Chinese herbal medicine trials: an elaborated checklist. Journal of Chinese Integrative Medicine, 2008, 6(3): 233-237.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
[1] Jun Cai, Hua Wang, Sheng Zhou, Bin Wu, Hua-rong Song, Zheng-rong Xuan. Effect of Sijunzi Decoction and enteral nutrition on T-cell subsets and nutritional status in patients with gastric cancer after operation: A randomized controlled trial. Journal of Chinese Integrative Medicine, 2008, 6(1): 37-40
[2] SUN Ming-yu, ZUO Jian, DUAN Ji-feng, HAN Jun, FAN Shi-ming, ZHANG Wei, ZHU Li-fang, YAO Ming-hui. Antitumor activities of kushen flavonoids in vivo and in vitro. Journal of Chinese Integrative Medicine, 2008, 6(1): 51-59
[3] Hai-feng Wei, Bai-liu Ya, Ling Zhao, Cui-fei Ye, Li Zhang, Lin Li. Evaluation of tongue manifestation of blood stasis syndrome and its relationship with blood rheological disorder in a rat model of transient brain ischemia. Journal of Chinese Integrative Medicine, 2008, 6(1): 73-76
[4] A-gao Zhou, Yong Zhang, Gang Kui, De-Yun Kong, Hai-liang Ge, Qiu-hua Ren, Jia-rong Dong, Sheng Hong, Xu-ming Mao, Yin Wang, Hui-zheng Zhang, Shu-jun Wang. Influence of traditional Chinese compound recipes with different efficacy on body weight, tumor weight and immune function in H22 cancer-bearing mice. Journal of Chinese Integrative Medicine, 2008, 6(1): 77-82
[5] Jing-yuan Mao, Chang-xiao Liu, Heng-he Wang, Guang-li Wei , Zhen-peng Zhang, Jie Xing, Wang Xian liang , Ying-fei Bi . Effects of Shenmai Injection on serum concentration and pharmacokinetics of digoxin in dogs with heart failure. Journal of Chinese Integrative Medicine, 2010, 8(11): 1070-1074
[6] Liang-ping Hu , Xiao-lei Bao, Xue Guan. Statistical inference and experimental design of univariate qualitative data of single-group design. Journal of Chinese Integrative Medicine, 2010, 8(11): 1085-1089
[7] Pedro Saganha João, Doenitz Christoph, Greten Tobias, Efferth Thomas, J. Greten Henry. Qigong therapy for physiotherapists suffering from burnout: a preliminary study. Journal of Chinese Integrative Medicine, 2012, 10(11): 1233-1239
[8] Nian-hong Wang , Jun-tao Yan , Wu-quan Sun , Yong-shan Hu , Jun Xia , Li-cheng Wei , Jie Jia , Gui-lin Ouyang , Yong He , Yan-ming Guo , Jie Xu . Effects of early application of Tuina treatment on quadriceps surface myoelectricity in patients after total knee arthroplasty: a randomized controlled trial. Journal of Chinese Integrative Medicine, 2012, 10(11): 1247-1253
[9] Peng-fei Gao, Kenji Watanabe. Introduction of the World Health Organization project of the International Classification of Traditional Medicine. Journal of Chinese Integrative Medicine, 2011, 9(11): 1161-1164
[10] Stephen D. Anton, Jonathan Shuster, Christiaan Leeuwenburgh. Investigations of botanicals on food intake, satiety, weight loss and oxidative stress: Study protocol of a double-blind, placebo-controlled, crossover study. Journal of Chinese Integrative Medicine, 2011, 9(11): 1190-1198